ASCO Annual Meeting: Multiple Myeloma | Conference

Philippe Moreau, MD, on Conclusions With VTd Plus Daratumumab in Newly Diagnosed Myeloma at ASCO 2021
July 15, 2021

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

Mounzer Agha, MD, Reviews the Safety Profile of Ciltacabtagene Autoleucel in Multiple Myeloma
July 10, 2021

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

Philippe Moreau, MD, on Results With Daratumumab Plus VTd in Newly Diagnosed Myeloma at ASCO 2021
July 08, 2021

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, on Response Rates From CARTITUDE-1 Trial at 2021 ASCO
July 03, 2021

Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Philippe Moreau, MD, on the Implications of Daratumumab Maintenance for Newly Diagnosed Multiple Myeloma
July 02, 2021

Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.

Saad Z. Usmani, MD, MBA, FACP, Details the Safety Profile for CARTITUDE-1 Trial
June 23, 2021

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

Mounzer Agha, MD, on Main Findings From CARTITUDE Studies at 2021 ASCO
June 16, 2021

Agha detailed updated findings from CARTITUDE-2 investigating cilta-cel for previously treated patients with multiple myeloma.

Higher Doses of Subcutaneous Elranatamab Show Efficacy in Relapsed/Refractory Myeloma
June 09, 2021

Subcutaneous Elranatamab had high response rates when given at or above 215 μg/kg.

Talquetamab Shows Durable and Continuous Response Treating R/R Multiple Myeloma
June 08, 2021

Data from the MonumentTAL-1 trial detailed the benefits with the recommended phase II dose of talquetamab to treat patients with relapsed/refractory multiple myeloma.

Phase 2 Recommended Dose of Teclistamab Shows Promising Safety, Efficacy in R/R MM
June 08, 2021

Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.